New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease First-time presentation of innovative biomarker-based translational clinical trial design to ...
AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the ...
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ...
Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback